Background and Objectives Fullerene-based compounds are a novel class of molecules being developed for a variety of biomedical applications, with nearly 1000 publications in this area in the last 4 years alone. One such compound, the e,e,e-methanofullerene(60)-63-tris malonic acid (designated C 3 ), is a potent catalytic superoxide dismutase mimetic which has shown neuroprotective efficacy in a number of animal models of neurologic disease, including Parkinsonian Macaca fascicularis monkeys. The aim of this study was to characterize its toxicity and pharmacokinetics in mice and monkeys. Methods To assess pharmacokinetics in mice, we synthesized and administered 14 C-C 3 to mice using various routes of delivery, including orally. To assess potential toxicity in primates, serial blood studies and electrocardiograms (ECGs) were obtained from monkeys treated with C 3 (3 or 7 mg/kg/day) for 2 months.
Introduction
C 60 fullerenes are spherical all-carbon molecules whose discovery 2 decades ago earned Kroto, Curl, and Smalley the Nobel Prize in Chemistry. The unique chemical and electronic properties of the fullerene carbon lattice confer potent antioxidant and anti-inflammatory properties on C 60 that have been exploited to develop potential therapeutics for a variety of diseases from cancer to Parkinson disease to aging. The parent C 60 fullerene molecule, however, is not soluble in water and forms aggregates in aqueous solutions, driving the need to synthesize water-soluble derivatives. One such compound, the e,e,e-methanofullerene(60)-63-tris malonic acid (designated C 3 ), is among the most extensively studied fullerene-based compounds (reviewed in [1] ). The chemical structure of C 3 as well as the contrast in solubility with native C 60 are shown in Fig. 1 . C 3 is an antioxidant with catalytic superoxide dismutase mimetic activity [2] which has neuroprotective efficacy in several mouse models of disease [1, [3] [4] [5] [6] [7] . In addition, chronic oral administration of C 3 produced a modest increase in lifespan [3, 8] and prevented cognitive deficits [3] in aging mice, arguing against toxicity at therapeutic doses, even with long-term administration. In addition, chronic systemic treatment with C 3 in a non-human primate model of Parkinson's disease for 2 months demonstrated significant behavioral and neuroanatomical improvement [9] . In that study, C3 treatment was started after degeneration of the nigral dopaminergic neurons was already in process. To date, however, no studies have characterized the tissue distribution, pharmacokinetics, or toxicology of C 3 .
Studies on pharmacokinetics and toxicity of other derivatives of fullerene C 60 have yielded conflicting data on biodistribution and in vivo toxicity [10] [11] [12] . This almost certainly reflects the nature and location of functional groups attached to the C 60 sphere that can dramatically affect physical properties like water solubility, protein binding, and biological activities of the molecule. In addition, in most of these studies, there was no characterization of the preparation being administered, including impurities, and for a number of these studies, subsequent work demonstrated that there was toxicity from unreacted material, or contaminants, not the C60-based compound itself. Because C 3 has shown efficacy in several standard animal models of CNS disease, we wanted to further characterize its toxicity and pharmacokinetics in two species, mice, and Macaque fascicularis monkeys. 14 C-C 3 carboxyfullerene are described in the Supplementary File.
Pharmacokinetic Studies in Mice
Mice were obtained from (Jackson Laboratory, Bar Harbor, ME, USA) at 8 weeks of age and housed in the vivarium barrier facility, under standard housing conditions, until 16 weeks of age (22-28 g), when used for experiments. All animal studies were approved by the Animal Care Programs at Washington University, and the University of California, San Diego, and are in accordance the PHS Guide for the Care and Use of Laboratory Animals, USDA Regulations, and the AVMA Panel on Euthanasia.
14 C-C 3 was administered to 10-week-old C57BL/6-J male mice by i.v. (intravenous), i.p (intraperitoneal)., p.o. (per os), and s.c. (subcutaneous) routes, or by surgically implanted intraperitoneal mini-osmotic pumps (Alza Pharmaceuticals, Palo Alto, CA, USA). Mice were given a single bolus of 1.1-mg/kg 14 C-C 3 , plus 9 X cold C 3 as a carrier (to minimize loss of radiolabeled C 3 on the syringe surface) in normal (0.9%) saline as the vehicle for the i.p., s.c., or i.v. (retro-orbital sinus) injections or in water for delivery by gastric gavage needle. Single day pumps (8 ll/h, 24-h duration) were loaded to deliver 17.5-mg/kg/day 14 C-C 3 (plus cold C 3 as carrier). Seven day (1 ll/h, 7-day duration) pumps were loaded to deliver 10-mg 14 C-C 3 /kg/day (with no cold C 3 carrier). Mice were anesthetized by inhaled metaphane prior to pump implantation. Blood (50-75 ll) was collected from the saphenous vein into heparinized capillary tubes at various times after drug administration. Each animal was bled three times and at least three blood samples were collected for each time point. Samples were either processed immediately or stored at -20°C overnight. Samples were analyzed by liquid scintillation counting (LSC). Animals were euthanized by pentobarbital injection followed by perfusion with ice-cold phosphatebuffered saline. The following tissues and organs were collected at the time of euthanasia for determination of radioactivity: bone (femur), brain, subcutaneous fat, heart, kidney, liver, lung, muscle, small intestine, spleen, and testis. Samples were weighed immediately and stored at -80°C until further processing. Tissue samples were macerated and homogenized directly in scintillation cocktail and analyzed for radioactive content.
Although the cyclopropane carbon of C 3 has previously been reported to be highly resistant to removal from the C 60 molecule, we performed studies to confirm that the 14 C label was retained on C 3 . First, we subjected C 3 to electrospray mass spectroscopy (ESI-MS) and found that the carboxyl carbons, but not the cyclopropane carbons, could be stripped from the C 3 molecule. In addition, when C 3 was exposed to solutions at pH 1 or pH 10 for[24 h at 37°C, a small fraction of carboxylic acid head groups were removed, but the cyclopropane carbons were intact.
To identify potential metabolites, HPLC analysis on plasma samples from mice injected with 14 C-C 3 was performed. Plasma was extracted into ethyl acetate using a two-phase extraction procedure [13] . The extraction was done at 4°C to minimize degradation during processing. The ethyl acetate fraction was evaporated and reconstituted in 0.1% trifluoroacetic acid (TFA) in water. The plasma extracts as well as aliquots of the original 14 C-C 3 sample were injected onto an Agilent 1100 HPLC system equipped with a C18 column. C 3 and potential metabolites were separated using a step-wise gradient starting at 95:5; A (= 0.1% TFA in water): B (= 95% isopropyl alcohol, 0.005% TFA, 5% water) and going to 5:95; A:B (final) over 40 min. Fractions (0.5 min) were collected and radioactivity measured.
Mouse Stroke Model and Surgical Procedures
Mice obtained from Jackson Labs at 8 weeks of age were housed in the vivarium barrier facility as above, until 4 months of age, when used for experiments. Male C57BL/ 6 J mice of 20-25-g weight were used to determine brain accumulation of C 3 after disruption of the blood-brain barrier. Focal reversible cerebral ischemia was induced by direct occlusion of the middle cerebral artery (MCA) as previously described [14] . Briefly, mice were anesthetized with ketamine (75 mg/kg) and xylazine (5 mg/kg). The right MCA was exposed by a 0.4-cm vertical skin incision midway between the right eye and ear. After splitting the temporalis muscle, a 1.5-2-mm burr hole was drilled at the junction of the zygomatic arch and the squamous bone. The right MCA was ligated distal to the lenticulostriate branches with an 11-0 suture under an operating microscope. Both common carotid arteries (CCAs) were then occluded using non-traumatic aneurysm clips (0.75 9 4 mm, from BRI, Rockville, MD, USA). Reduction in blood flow was confirmed by laser doppler. At the end of a 15 min ischemic period, the right MCA ligature and both CCA clips were released, and restoration of blood flow was confirmed visually and by laser doppler. Rectal temperature was recorded and maintained at 37.0 ± 0.5°C prior to and for [1 h after MCA ligation. All mice were housed in an air-ventilated room at 24 ± 0.5°C. 14 C-C 3 (1.1 mg/kg) was injected i.p. at 16 or 24 h post-surgery, the period during which blood-brain barrier breakdown occurs in this model [14] . At 24 or 36 h after ischemia, mice were anesthetized, decapitated, and the cortical hemispheres dissected. Tissue samples were frozen on dry ice, and the ipsilateral and contralateral cortices weighed.
C 3 -Binding Properties in Mouse Blood and Plasma
Partitioning of C 3 between plasma and cellular components of blood was determined as follows. Whole blood spiked with 14 C-C 3 or blood collected from animals dosed with radiolabeled C 3 was centrifuged (1000 9 g, 15 min), with the supernatant defined as the plasma fraction and the pellet as the cellular component. Cells were resuspended in phosphate-buffered saline (PBS) and centrifuged again. The second PBS supernatant was defined as wash and the pellet as washed cells. The samples were analyzed by LSC. To examine the plasma protein binding of C 3 , plasma was prepared from freshly collected heparinized whole blood by centrifugation (1000 9 g, 15 min). Radiolabeled C 3 was added to saline (0.9%) or to plasma at 10 or 100 lg/ml and incubated for 1 h. The samples were passed through a 3000 mwco Centricon (Millipore Corp., Bedford, MA, USA) filter (m.w. of C 3 is 1027). Filtrate and retained solution were analyzed for radioactivity, with radioactivity in the filtrate defined as free C 3 and that in the retained solution as protein-bound C 3 .
Excretion of C 3 in Mice
Urine samples were collected from 30 min up to 48 h after i.p. dosing with radiolabeled C 3 , and up to 7 days after implanting a 7-day Alzet pump. Radioactivity was determined per ll urine. Data were transformed to the amount of 14 C-C 3 excreted per ml urine at the time of collection. Fecal material was collected from 0 to 48 h after dosing and extracted for radioactivity by dissolving fecal material in acidified aqueous methanol followed by three extractions with ethyl acetate (3:1 vol:vol).
Evaluation of the Effects of C 3 on Physiology,
Hematology, and Serum Chemistry in Macaca fascicularis Monkeys A group of 15 male M. fascicularis monkeys (age 5-10 years) which were enrolled in a vehicle-controlled study testing C 3 in a model of Parkinson disease, using intracarotid 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP 0.25 mg/kg) injection [9] , also served here as subjects to evaluate the effect of C 3 on hematology, blood chemistry, and heart function. Care was taken throughout the study to keep all investigators blinded to the treatment group. As we previously reported [9] , monkeys were fasted overnight, anesthetized with ketamine, and intubated and given inhaled isoflurane to maintain anesthesia. An 80 cm catheter was guided from the femoral artery into the internal carotid artery utilizing fluoroscopic guidance. MPTP (0.25 mg/kg) was then infused into the animal. At 10 days following MPTP, monkeys were implanted with Alzet pumps subcutaneously to deliver a chronic infusion of either C 3 (3-5 mg/kg/day) or food coloring for a total treatment duration of 2 months (one pump exchange was performed after 1 month). Following the 2-month treatment period with either C 3 or food coloring, monkeys given MPTP had blood drawn for hematology and serum chemistry. Two additional control monkeys, which were not lesioned with MPTP, were given C 3 (7 mg/kg/day) for 1 month. Electrocardiograms were recorded at baseline (prior to MPTP), after MPTP, after 1 month of placebo or C 3 , and after 2 months of placebo or C 3 , from all animals.
Pharmacokinetic Studies in Monkeys
We had the fortuitous opportunity to determine pharmacokinetics of C 3 in two monkeys which were naïve to any previous experimental procedures, including MPTP lesioning. Each was fasted overnight; anesthesia was induced with ketamine (10 mg/kg i.m.) and maintained with inhalation of isoflurane (1-3%). Alzet osmotic pumps loaded to deliver 7 mg/kg/day for 1 month were implanted subcutaneously between the scapulae. Blood was drawn at 1.5, 3, 24 h, 1 week, and 1 month after implantation. Plasma was separated, and the samples were run in triplicate on an ELISA plate prepared with anti-C 60 antibody which also recognizes C 3 [15, 16] . Non-specific background was determined on plasma lacking C 3 .
Pharmacokinetic Calculations
The area under the curve (AUC) was calculated from the blood-level radioactivity from animals using the area function of Sigma Plot (SPSS, Inc, Chicago. IL, USA). The first-order rate constant (k) was determined with the regression analysis component of Sigma Plot software. Other parameters were as follows: plasma half-life, t 1/
Animal Care and Use
The study was approved by the Institutional Animal Care and Use Committee (IACUC) of Washington University in St. Louis and the non-human primate studies were conducted in the Non-human Primate Facility at the Washington University School of Medicine. All procedures were designed to conform to suggestions of the 2006 Weather all Report with steps taken to ameliorate subject suffering in accordance with the requirements of the National Institutes of Health (NIH, USA). In the event of mild-to-moderate pain or discomfort, a primate would be treated with Buprenex, 0.01-0.03 mg/kg for up to 3 days, per the discretion of the staff veterinarian. No animals were knowingly exposed to potential infection and humane endpoints were pre-defined and applied, if necessary, to reduce subject discomfort. The macaques were housed in appropriate animal facilities with 12-h day and 12-h night cycles. They were provided with food, water ad libitum, toys, and movies as enrichment activities. All animals were housed in the same USDA-approved facility room in cages that met or exceeded the Weatherall Report's requirements. The monkeys were monitored daily by the researchers, animal care staff, and a veterinarian, to check their general health and welfare. All routine animal care procedures have been described in detail [17] .
Results

Pharmacokinetics of 14 C-C 3 in Mouse Blood
Peak blood levels occurred approximately 1 h after administration of drug by i.p., s.c. or p.o. (Table 1 , Fig. 2a) . However, following i.v. administration, there was an initial 1 h phase of rapid elimination followed by a second slower phase that was similar to that observed with i.p. s.c., or p.o. administration (Fig. 2a) . Blood levels of C 3 from 3 to 24 h, regardless of route of administration, followed first-order decay kinetics with a plasma half-life of 8.2 ± 0.2 h (Table 1 , Fig. 2a) . As discussed below, we found that [99% of blood C 3 was in the plasma; therefore, the reported blood levels reflect plasma levels for C 3 . The effect of chronic administration by mini-osmotic pump on blood levels of C 3 was then investigated. Mice were implanted with 1-day or 7-day pumps and blood samples collected and analyzed for radioactivity (Fig. 2b,  c) . Levels of C 3 increased for 24 h following 1-day pump implantation, after which the blood level declined with first-order decay (Fig. 2b) . At 48 h after the 1-day pump was depleted, blood levels were less than 6% of the peak blood concentration. Following implantation of the 7-day pump, C 3 blood levels, as expected, increased at a fairly constant linear rate of 0.96 lg/day (Fig. 2c) .
Behavior of C 3 in Mouse Blood and Plasma
To determine to what extent C 3 partitions into blood cells versus plasma, the distribution and plasma protein binding of C 3 was evaluated in blood collected from C 3 -treated animals and in naïve blood spiked with 14 C-C 3 . More than 99% of 14 C-C 3 partitioned into the plasma fraction and was separable from the cell pellet by centrifugation. To measure C 3 plasma protein binding, plasma and saline were spiked with 10-or 100-lg/ml 14 C-C 3 and centrifuged through 3000 mwco centricon filter units (C 3 m.w. = 1027). Both concentrations of C 3 behaved identically. After centrifugation, 73% of the 14 C-C 3 was in the filtrate of the saline control compared to 13% of the plasma filtrate, indicating that 87 ± 0.1% (mean ± SEM) of C 3 was protein bound.
Plasma samples obtained at 2, 8 h (one plasma half-life) and 18 h (about two plasma half-lives) after i.p. administration of 14 C-C 3 were analyzed by HPLC to determine stability of the 14 C-label on C 3 in vivo. Radioactivity was extracted from plasma, with an efficiency of 96 ± 2%. The HPLC chromatograms for eluted radioactivity are shown in Fig. 3 . 
Tissue Distribution of C 3 in Mice
After a single intraperitoneal (i.p.) dose of 14 C-C 3 , radioactivity distributed to all tissues examined (Fig. 4a) , with highest uptake into kidney and liver. There was no difference in distribution between i.p. and i.v. routes of administration (data not shown). On the other hand, animals with 1-day implanted pumps showed tissue radioactivity levels that were higher than in animals which received a single i.p. or i.v. bolus, suggesting that chronic delivery can increase loading into tissues (note scale). When adjusted for differences in dose, tissue levels of radioactivity in animals with surgically implanted 7-day pumps were five times higher than that in animals given a single bolus dose ( Fig. 4b ; only data from 7-day pumps are not shown). Surprisingly, muscle and heart had the lowest levels of radioactivity of all the tissues examined, while liver and kidney exhibited the highest levels. The half-life for renal elimination was calculated to be approximately 150 h compared to the shorter plasma clearance t 1/2 of 8.2 ± 0.2 h. The amount of radioactivity remaining in the whole liver 144 h after a single i.p. administration of 1.1 mg/kg was about 10.6% of the administered dose and that in each kidney was about 2.2% of the dose.
Delivery of C 3 to Mouse Brain
We examined distribution of C 3 into brain under normal conditions and after disruption of the blood-brain barrier, since systemic administration of C 3 has shown neuroprotective effects [5, 18, 19] . Following i.p. administration of compound in mice, levels of C 3 in brain were highest at 3 h, the earliest time point examined, and declined by half at 6 h (Fig. 5a ). Similar to other tissues examined, radioactivity in the brains of mice with compound delivered by the 7-day osmotic pump was higher than i.p. C-C 3 in mice. Similar amounts of total radioactivity were chromatographed for each sample. C 3 elutes at 27 min, with the two minor mono-decarboxylation products, present in the original preparation, appearing at 31 and 40 min, respectively. Both the 2-h and 18-h plasma samples were essentially identical to the original C 3 stock. i.p intraperitoneal administration (Fig. 5b) . To determine whether increased permeability of the blood-brain barrier would enhance delivery of C 3 to brain, we measured C 3 uptake in mice subjected to focal cerebral ischemia using a model that disrupts blood-brain barrier on the ipsilateral (ischemic) side [14] . After ischemia, C 3 levels in the ipsilateral hemisphere were twice as high as in the undamaged contralateral cortex (Fig. 5c) . Accumulation of 14 C-C 3 in the ischemic hemisphere was even greater than in uninjured brain, indicating that disruption of the blood-brain barrier can significantly increase brain penetration, a feature that might be used to advantage to deliver higher concentrations of compound to injured tissue.
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Mouse Excretion of C 3
The urinary excretion of 14 C-C 3 was assayed for 24 h after i.p. administration in mice. The concentration of radioactivity in urine showed two phases of decay (Fig. 6) . The initial phase lasted for 3 h after compound administration, corresponding to the period of accumulation seen in blood (Fig. 2) . The second phase of decreasing concentration was tracked for 24 h after dosing. The two phases of decay suggested elimination from two compartments, most likely plasma initially, then kidney.
Levels in liver were high after i.p. administration. Fecal extractions showed that 12 ± 2.7% of the administered dose was excreted by liver during the first 24 h, and 6.6 ± 2.2% was excreted from 24 to 48 h, suggesting that a substantial amount of drug was eliminated hepatically. Urinary excretion was approximately 5.5% of the administered dose in the first 24 h following i.p. administration. The urine concentration of radioactivity remained relatively constant at 23 ± 1.8 lg/ml during chronic administration via 7-day pump.
Evaluation of Toxicity of C 3 in Mice
We determined that the LD 50 for C 3 in mice was 80 mg/kg after, a single i.p. injection. In addition, we evaluated 14 C-C 3 uptake into the brain was increased by chronic administration (b). Focal brain ischemia was surgically induced by 10-15 min arterial restriction followed by i.p. administration of 14 C-C 3 (c). Samples consisting of the focal lesion area (ipsilateral) and contralateral normal tissue were collected, homogenized, and subjected to liquid scintillation counting. 14 C-C 3 levels in the damaged tissue were higher than in undamaged tissue. Data represent sample mean ± SEM (n = 6). i.p intraperitoneal chronic delivery of 30 mg/kg/day for 2 months, which produced no deaths, thus the LD 50 was[30 mg/kg/day for 2 months.
Plasma Levels of C 3 , Blood Chemistry, and Heart Function in Monkeys
Plasma levels of C 3 in two monkeys that received C 3 , 7 mg/kg/day for 28 days, were analyzed by an ELISA developed by Dr. Bernard Erlanger, Columbia University, based on an anti-fullerene antibody that recognized C 3 . The results from these two monkeys and the expected plasma levels for this dose based on the mouse data are shown in Table 2 . Using allometric scaling calculations between mice and monkeys receiving the same dose of drug, we observed the expected higher plasma concentration in monkeys (Table 2) . We then measured effects of C 3 on blood chemistry (Fig. 7) and hematology (Fig. 8) parameters in monkeys chronically treated with C 3 (3 mg/kg/day, 60 days) and compared to placebo. These monkeys were part of a study using unilateral intracarotid MPTP injection as a model of Parkinson Disease, and both sets of monkeys underwent identical procedures throughout the study. There was no difference in any measure between experimental groups, and all values were within the normal range for this species [20] . ECGs were also performed, and no differences in electrical activity or ECG intervals were observed between the two treatment groups (Table 3) .
Discussion and Conclusions
Fullerenes and carbon nanotubes are being developed for a broad range of biological applications; including Gd-endohedral (Gd@C60) MRI contrast agents, anti-cancer therapeutics, and neuroprotective agents. Many fullerene derivatives have antioxidant properties, and a small number of compounds, including C 3 , are highly effective catalytic superoxide dismutase mimetic antioxidants [16] . The C 3 compound is also amphipathic, demonstrating excellent solubility in water ([400 mM as the sodium salt), but with good entry into biological lipid bilayers [5] . Thus, we expected that C 3 would show good tissue uptake. Consistent with this, we found that absorption of C 3 into blood after both s.c. or i.p. injections was rapid, with peak blood levels observed 1 h after injection. In addition, peak levels for both routes of administration were similar. After the first hour, all four routes of drug administration used for this study (i.v., i.p., s.c., and p.o.) produced plasma levels that followed similar first-order kinetics, with a plasma t of 8.2 ± 0.2 h. This is relatively similar to the 6.8 h t reported for another water-soluble C 60 derivative, MSCAD-C60 [11] . Plasma levels of C 3 measured in two M. fascicularis given C 3 (7 mg/kg/day) by chronic subcutaneous infusion via osmotic pumps. Using allometric scaling to compare expected blood levels between monkeys and mice receiving the same administered dose, we used the following calculations. The K m for mice was 4.5, based on the 35 g mice used here, and for monkeys, was 9.5 [23] . Thus, the same dose should produce 9.5/4.5 = 2.1 times higher levels in monkeys compared to mice. The expected concentrations of C 3 in monkey plasma based on data from mice given a similar dose (in the last column) and are predicted well by these scaling calculations [23] . Values are mean ± SEM (n = 6) Elimination of C 3 from blood also conformed to firstorder kinetics, suggesting that there was a little redistribution of compound from tissue compartments back into plasma. The observation that chronic delivery of drug did not modify the t indicated that clearance was not due to an inducible transport system.
Oral bioavailability of C 3 as an aqueous solution was * 10% of the i.v. administration. However, many if not most, drugs require either formulation or administration Fig. 7 Blood chemistry studies in Macaque fascicularis monkeys. Blood was drawn just before induction of anesthesia (P) prior to injection of MPTP; 7 days after MPTP just before initiating treatment with C 3 or placebo (M); after 1 month of treatment with C 3 or placebo (1mo), and after 2 months of treatment with C 3 or placebo (2mo). MPTP = 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine without (or sometimes with) food for optimal GI bioavailability. We did not attempt to modify the oral delivery system to improve gut uptake of C3, but speculate that administration before feeding would increase enteric absorption of C 3 , a standard industry method for increasing enteric absorption of drugs with some degree of protein binding, as C 3 exhibits. After single-dose and chronic administration, C 3 exhibited broad tissue distribution with detectable levels in all tissues analyzed. However, the highest tissue uptake was by liver (25% at 3 h) and kidney (20% at 3 h). These data are consistent with two previous pharmacokinetic studies of other fullerene derivatives that found accumulation predominantly in liver and kidney [11, 12] . In the report by Cagle (1999) , their polyhydroxylated holmium metallofullerene preparation also accumulated significantly in bone [12] , but we found only trace amounts of C 3 in bone, even with chronic administration. Excretion of C 3 through these two routes accounted for 17.5% of the administered dose during the 24 h following i.p. administration, indicating that a substantial percentage of C 3 is cleared by both liver and kidney. Fecal excretion was an important route of clearance, suggesting that the liver accumulation of C 3 we observed reflected compound that was in the process of being excreted by the biliary system. During 7-day pump administration, animals also excreted an estimated 10-20% of the administered dose per day in the urine. C 3 continued to be excreted by renal and hepatic routes after blood levels had become undetectable, with nearly 100% of the administered dose cleared 48 h after the last dose.
We were specifically interested in determining brain uptake of C 3, because several groups have reported neuroprotection by C 3 (reviewed in [1] ), including protection after MPTP-induced brain injury in non-human primates [9] . C 3 was detected in brain after single-dose i.p. or chronic pump administration (Fig. 5) , and levels were higher than levels achieved by several drugs known to cross the blood-brain barrier, and to have central nervous system (CNS) activity. For example, the brain Mean ± SD, n = 5 each Fig. 8 Hematology studies in Macaque fascicularis monkeys. Blood was obtained as described in Fig. 7 concentration of the serotonin-selective reuptake inhibitor antidepressant sertraline (Zoloft) in rats after 5 mg/kg p.o. was * 0.5-1% of the administered dose [21, 22] . In comparison, after a single bolus of C 3 , the concentration in brain was 2% of delivered dose, which increased to approximately 4% during chronic systemic delivery. Disruption of the blood brain barrier by mild focal cerebral ischemia further increased uptake to 10% of the administered dose.
To estimate a therapeutic window, we determined an LD 50 for C 3 in mice. This was 80 mg/kg for a single i.p. injection and [30 mg/kg/day for chronic delivery lasting 2 months (no deaths occurred at this dose, higher doses were not tested). Biologically effective doses of C 3 have been on the order of 5-10 mg/kg for a single dose, or 0.5-10 mg/kg/day (which is 0.02-0.4 mg/kg/h) for chronic delivery (for up to 24 months). Thus, C 3 appears to have a broad therapeutic window. Here, we did not explore embryotoxicity of C3, information that would be important for studies in reproductive-age organisms, but a previous study in which C 3 was administered to pregnant mouse dams for 30 days failed to find any effects on fertility, pregnancy, viability, or anatomy of the offspring [2] .
Examination of the impact of chronic C 3 treatment (3-7 mg/kg) on M. fascicularis monkeys showed that blood chemistry, hematology, and ECGs were unchanged and remained within the normal range during a 1-2-month treatment period with C 3 . These doses are within the biologically effective range in mice. In addition, we found the plasma half-life of C 3 was 8 ± 1 h, which was similar to that in mice. Data from these primate studies may be a valuable tool for determining treatment strategies for evaluating the effectiveness of C 3 against an array of injury and disease models in non-human primates and possibly humans.
In summary, C 3 has favorable pharmacokinetics and a wide therapeutic index. C 3 distributes into all tissues studied, including brain, albeit at much lower levels than kidney and liver, which are the main sites of excretion. Chronic administration of drug provided higher brain levels of C 3 than bolus injection as did disruption of the blood-brain barrier. Information from this study may assist in rational drug design to increase delivery to the target tissues (e.g., brain) and should also help to guide further in vivo studies investigating therapeutic efficacy and structure-activity relationships of C 3 and related malonic C 60 compounds.
